Korean biotech startup Trioar, which develops antibody-drug conjugate (ADC) platform technologies, has secured $1.8 million (2.5 billion won) in new funding from CKD Venture Capital. This latest investment brings the company’s total Series B funding to over $18 million (25 billion won).

Trioar’s Series B round is being conducted through a multi-closing structure. Previous tranches included participation from IMM Investment, KB Investment, LSK Investment, Shinhan Capital (co-GPs: Jin & Investment Partners, Regent Partners, Sneak Peak Investment), Kiwoom Investment, Woori Venture Partners, Hyundai Technology Investment, and Shinhan Venture Investment.

CKD Venture Capital’s participation stems from connections made at the “2025 Seoul Bio Hub IR DAY: Seoul Bio Fund Manager Meetup” held last June. The event demonstrates how Seoul Bio Hub’s platform programs are translating into tangible investment outcomes for biotech startups.

Seoul Bio Hub operates as a specialized incubation center established by the Seoul Metropolitan Government to systematically support the launch and growth of biotech and medical startups. Beyond providing workspace, the hub offers comprehensive support including mentoring, education, commercialization assistance, and investment connections.

“Seoul Bio Hub goes beyond simply providing office space,” said Seongho Woo, CEO of Trioar. “Through various networking events and IR sessions, it creates real investment opportunities, making it a genuine growth platform for biotech startups. Our successful fundraising from CKD Venture Capital was made possible thanks to Seoul Bio Hub’s excellent support system.”

Trioar is revolutionizing the therapeutic index of ADC treatments through its proprietary platform technology.